MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • News
  • Store
  • Brokers
  • Download
  • Economic Calendar
  • Trading Signals
  • WebTerminal
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Türkçe Türkçe
ArriVent BioPharma, Inc. Common Stock

AVBP

#2111
ArriVent BioPharma, Inc. Common Stock
22.97
+0.22%
Sector:
Base:
Profit Currency:
Daily Range
22.93
22.97
Year Range
15.47
26.00
Daily Change
+0.22%
Monthly Change
-1.20%
6 month change
+19.57%
Year Change
-4.01%
Previous Close
22.92
Open
22.93
Bid
Ask
Low
22.93
High
22.97
Volume
76
  1. Markets
  2. US Stock Market
  3. Healthcare
  4. AVBP
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25 TTM

News

Investing Investing
AVBP
2026.01.16
Cantor Fitzgerald ribadisce il rating Overweight per le azioni ArriVent
Investing Investing
AVBP
2026.01.16
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Investing Investing
AVBP
2026.01.06
Oppenheimer conferma il rating Outperform per le azioni di ArriVent BioPharma
Investing Investing
AVBP
2026.01.06
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock
Seeking Alpha Seeking Alpha
AVBP
2026.01.04
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy
Seeking Alpha Seeking Alpha
AVBP
2025.12.25
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)
Investing Investing
AVBP
2025.12.22
Cantor Fitzgerald inizia la copertura di ArriVent BioPharma con rating Overweight
Investing Investing
AVBP
2025.12.22
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating
Investing Investing
AVBP
2025.12.22
ArriVent dosa il primo paziente nello studio pivotale di fase 3 per farmaco contro il cancro al polmone
Investing Investing
AVBP
2025.12.22
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug
Investing Investing
AVBP
2025.12.10
ArriVent BioPharma: BTIG avvia copertura con rating Buy per potenziale oncologico
Investing Investing
AVBP
2025.12.10
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential

Markets

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Charts & Ideas

  • Trading Ideas
  • Education Ideas
  • Charts

MQL5 Community

  • Market
  • Signals
  • Forum
  • Articles
  • CodeBase

News

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Brokers

  • All Brokers
  • Forex
  • Stock
  • Metals
MetaTrader 5
MQL5 Channels
Economic Calendar
Disclaimer and Risk Disclosure Terms of Use Contacts and Requests Legal
Copyright 2000-2026, MetaQuotes Ltd